cobas eplex respiratory pathogen panel 3
GenMark Diagnostics, Inc. · Decision date Oct 30, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on October 30, 2026 for K262938, the cobas eplex respiratory pathogen panel 3 submitted by GenMark Diagnostics, Inc. of Carlsbad, California. The submission was received August 21, 2026 and reviewed under 21 CFR 866.3981 in the Microbiology specialty, product code QOF, Class II. The listed predicate is the BioFire Respiratory Panel 2.1 (DEN200031). SESE denotes 510(k) clearance, not PMA approval.
The device is a multiplexed nucleic acid in vitro diagnostic test for use on the cobas eplex system, intended for simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs from individuals with signs and symptoms of respiratory tract infection. The summary describes competitive nucleic acid hybridization in a sandwich assay format with PCR and/or RT-PCR amplification. The source does not state the full intended-use wording, performance results or any clearance conditions beyond the decision record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262938
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- GenMark Diagnostics, Inc.
- Product code
- QOF
- Decision code
- SESE
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.
- Applicant
- GenMark Diagnostics, Inc.
- Product code
- QOF
- FDA device class
- 2
FDA decision timeline
K262938 received
Application receipt date recorded by FDA.
K262938 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QOF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Xpert Xpress CoV-2/Flu plusK263333 | Cepheid | 510(k) clearance | Oct 22, 2026 | FDA |
Xpert Xpress CoV-2/Flu plusK263120 | Cepheid | 510(k) clearance | Oct 2, 2026 | FDA |
Xpert Respiratory PanelK261336 | Cepheid | 510(k) clearance | Sep 25, 2026 | FDA |
| Biofire Diagnostics | 510(k) clearance | Sep 22, 2026 | FDA | |
| Baebies, Inc. | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
GenMark Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Carlsbad, CA
Sources and methodology
- Original FDA record: K262938
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


